The Role of Angiogenesis in Melanoma: Clinical Treatments and Future Expectations

Overview

Journal Front Pharmacol

Date 2023 Jan 2

PMID 36588679

Authors

Zhuzhu Wu

Yifei Bian

Tianjiao Chu

Yuman Wang

Shuai Man

Yongmei Song

Zhenguo Wang

Affiliations

Soon will be listed here.

Abstract

The incidence of melanoma has increased rapidly over the past few decades, with mortality accounting for more than 75% of all skin cancers. The high metastatic potential of Melanoma is an essential factor in its high mortality. Vascular angiogenic system has been proved to be crucial for the metastasis of melanoma. An in-depth understanding of angiogenesis will be of great benefit to melanoma treatment and may promote the development of melanoma therapies. This review summarizes the recent advances and challenges of anti-angiogenic agents, including monoclonal antibodies, tyrosine kinase inhibitors, human recombinant Endostatin, and traditional Chinese herbal medicine. We hope to provide a better understanding of the mechanisms, clinical research progress, and future research directions of melanoma.

Citing Articles

Preclinical pharmaco-toxicological screening of biomimetic melanin-like nanoparticles as a potential therapeutic strategy for cutaneous melanoma.

Marcovici I, Chioibas R, Zupko I, Pinzaru I, Moaca A, Ledeti A Front Pharmacol. 2025; 16:1487854.

PMID: 39981176 PMC: 11839674. DOI: 10.3389/fphar.2025.1487854.

Melanoma-derived extracellular vesicles transfer proangiogenic factors.

Wilczak M, Surman M, PRZYBYlO M Oncol Res. 2025; 33(2):245-262.

PMID: 39866233 PMC: 11753996. DOI: 10.32604/or.2024.055449.

Advances in Melanoma: From Genetic Insights to Therapeutic Innovations.

Valdez-Salazar F, Jimenez-Del Rio L, Padilla-Gutierrez J, Valle Y, Munoz-Valle J, Valdes-Alvarado E Biomedicines. 2024; 12(8).

PMID: 39200315 PMC: 11351162. DOI: 10.3390/biomedicines12081851.

Unveiling the Dynamic Interplay between Cancer Stem Cells and the Tumor Microenvironment in Melanoma: Implications for Novel Therapeutic Strategies.

Limonta P, Chiaramonte R, Casati L Cancers (Basel). 2024; 16(16).

PMID: 39199632 PMC: 11352669. DOI: 10.3390/cancers16162861.

Molecular Imaging of Melanoma VEGF-expressing Tumors through [Tc]Tc-HYNIC-Fab(Bevacizumab).

Camacho X, Perroni C, Alfaya L, Cabrera M, Tassano M, Garcia M Anticancer Agents Med Chem. 2024; 24(18):1347-1359.

PMID: 39129293 DOI: 10.2174/0118715206294297240805073550.

References

Okamoto K, Kodama K, Takase K, Sugi N, Yamamoto Y, Iwata M . Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013; 340(1):97-103. DOI: 10.1016/j.canlet.2013.07.007. View

Liu S, Zhao H, Hu Y, Yan C, Mi Y, Li X . Lactate promotes metastasis of normoxic colorectal cancer stem cells through PGC-1α-mediated oxidative phosphorylation. Cell Death Dis. 2022; 13(7):651. PMC: 9329320. DOI: 10.1038/s41419-022-05111-1. View

Zhang Q, Lu S, Li T, Yu L, Zhang Y, Zeng H . ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. J Exp Clin Cancer Res. 2019; 38(1):173. PMC: 6482513. DOI: 10.1186/s13046-019-1156-5. View

Laurenzana A, Chilla A, Luciani C, Peppicelli S, Biagioni A, Bianchini F . uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells. Int J Cancer. 2017; 141(6):1190-1200. DOI: 10.1002/ijc.30817. View

Hong D, Kurzrock R, Wheler J, Naing A, Falchook G, Fu S . Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015; 21(21):4801-10. PMC: 4840931. DOI: 10.1158/1078-0432.CCR-14-3063. View

Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick A, Stur E, Hanjra P . Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Rep. 2022; 39(12):110999. PMC: 9272813. DOI: 10.1016/j.celrep.2022.110999. View

Tarhini A, Frankel P, Ruel C, Ernstoff M, Kuzel T, Logan T . NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018; 124(22):4332-4341. PMC: 6504933. DOI: 10.1002/cncr.31734. View

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

Ghitu A, Schwiebs A, Radeke H, Avram S, Zupko I, Bor A . A Comprehensive Assessment of Apigenin as an Antiproliferative, Proapoptotic, Antiangiogenic and Immunomodulatory Phytocompound. Nutrients. 2019; 11(4). PMC: 6521017. DOI: 10.3390/nu11040858. View

10.

Choi G, Kim D, Oh J . AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer. Front Pharmacol. 2021; 12:660313. PMC: 8356077. DOI: 10.3389/fphar.2021.660313. View

11.

Qin S, Li A, Yi M, Yu S, Zhang M, Wu K . Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019; 12(1):27. PMC: 6417086. DOI: 10.1186/s13045-019-0718-5. View

12.

Tong M, Wang J, Zhang H, Xing H, Wang Y, Fang Y . Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials. J Cancer. 2019; 10(4):968-978. PMC: 6400798. DOI: 10.7150/jca.26672. View

13.

Muppala S, Xiao R, Krukovets I, Verbovetsky D, Yendamuri R, Habib N . Thrombospondin-4 mediates TGF-β-induced angiogenesis. Oncogene. 2017; 36(36):5189-5198. PMC: 5589494. DOI: 10.1038/onc.2017.140. View

14.

Li D, Xie K, Ding G, Li J, Chen K, Li H . Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. Cancer Lett. 2013; 346(1):45-52. DOI: 10.1016/j.canlet.2013.12.004. View

15.

Feichtinger R, Lang R, Geilberger R, Rathje F, Mayr J, Sperl W . Melanoma tumors exhibit a variable but distinct metabolic signature. Exp Dermatol. 2017; 27(2):204-207. DOI: 10.1111/exd.13465. View

16.

Kuczynski E, Reynolds A . Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis. 2019; 23(1):55-74. DOI: 10.1007/s10456-019-09698-6. View

17.

Parmar D, Apte M . Angiopoietin inhibitors: A review on targeting tumor angiogenesis. Eur J Pharmacol. 2021; 899:174021. DOI: 10.1016/j.ejphar.2021.174021. View

18.

Yuan S, Fu Q, Zhao L, Fu X, Li T, Han L . Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. Oncologist. 2022; 27(6):e463-e470. PMC: 9177116. DOI: 10.1093/oncolo/oyab068. View

19.

Koo H, Kume T . FoxC1-dependent regulation of vascular endothelial growth factor signaling in corneal avascularity. Trends Cardiovasc Med. 2012; 23(1):1-4. PMC: 3525780. DOI: 10.1016/j.tcm.2012.08.002. View

20.

Shin S, Cho H, Das R, Gil-Henn H, Ramakrishnan S, Al Bayati A . Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases. Cells. 2021; 10(11). PMC: 8616280. DOI: 10.3390/cells10112904. View